Built with thought-leaders at Sage Therapeutics, Janssen and Lundbeck the 2nd Annual Neuropsychiatric Drug Development Summit (NPD) will unravel the complexities of developing truly clinically transformative neuropsychiatric drugs.

With an emphasis on depressive disorders, this industry defining meeting will

  • Investigate ketamine’s effects on opioid receptors in the brain
  • Decipher which biomarkers are a predictor of patient response rate
  • Share advances in clinical trial design to overcome challenges associated with placebos

Uniting 90+ drug developers from all corners of the world, NPD will be your opportunity to discuss, in depth, the challenges with preclinical models, precision medicine and target selection that have been stifling the progress of your neuropsychiatric drug development.

Connect with WCG at the conference

  • To schedule a meeting with a WCG representative during the event, please complete the form.